Natalie McNamee

Natalie McNamee

Private Equity Investor bij Tarnagulla Ventures Pty Ltd.

Consumer Services
Health Technology
Finance

Profiel

Natalie has been a Director of Tarnagulla Ventures Pty Ltd since 2015.
She had led the investment diligence into most of the portfolio companies since then, including Lubris BioPharma, a company which has since successfully licensed their lead indication to Novartis.
Prior to returning to Australia, Natalie worked for Tocagen Inc, a gene therapy company, based in San Diego, in their business development team whilst finishing her Masters.
She then worked as a bioengineer at the then-newly formed Quanticel Pharmaceuticals, a cancer stem cell focused drug developer.
Quanticel was acquired by Celgene for $485M in 2015.
Natalie received her Masters in Bioengineering at UC San Diego and a dual Bachelor of Finance and Mechanical Engineering from Melbourne University.

Actieve functies van Natalie McNamee

BedrijvenFunctieBegin
Private Equity Investor 01-01-2015
Alle actieve functies van Natalie McNamee

Eerdere bekende functies van Natalie McNamee

Opleiding van Natalie McNamee

University of California San Diego Graduate Degree
University of Melbourne Undergraduate Degree

Ervaring
Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Ervaring van Natalie McNamee in detail bekijken

Connecties

1

Eerstegraads connecties

4

Bedrijven verbonden in de eerste graad

Man

Vrouw

Besturend

Uitvoerend

Persoonlijk netwerk weergeven

Verwante bedrijven

Bedrijven in privébezit2

Health Technology

Finance

Zie bedrijfsconnecties
  1. Beurs
  2. Insiders
  3. Natalie McNamee